The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...

CRISPR Therapeutics' stock decline is likely ... last week Intellia just announced its own layoff and discontinuation of a major clinical trial as well, indicating that it too is starting to ...

BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene ... molecular biology research, and cleanroom ...